Hypothesis

We hypothesize that accumulation of heteroplasmic mitochondrial DNA (mtDNA) mutations in podocytes directly triggers nuclear senescence programs through a retrograde signaling cascade that involves cytosolic mtDNA sensing, cGAS-STING activation, and subsequent histone lactylation‑mediated opening of the p16INK4a promoter. Restoring mtDNA copy number or preventing heteroplasmic expansion will block this cascade and suppress p16/p21 induction, thereby delaying glomerular aging.

Mechanistic Rationale

1. mtDNA Heteroplasmy and Cytosolic Release – Podocytes exhibit high oxidative phosphorylation demand, making their mtDNA prone to replication errors. Heteroplasmic mutants reduce membrane potential, impair PINK1/Parkin‑mediated mitophagy, and increase the likelihood of mtDNA efflux via VDAC or mitochondrial-derived vesicles. This step is supported by observations that urinary mtDNA copy number reflects renal injury and precedes GFR decline [3].
2. cGAS‑STING as the Primary Sensor – Cytosolic mtDNA binds cGAS, producing 2’3’‑cGAMP and activating STING. In renal tubular cells, this pathway drives NLRP3 inflammasome formation and p16INK4a upregulation [1]. We propose that in podocytes, sustained STING signaling leads to TBK1‑dependent phosphorylation of histone H3 lactate (H3K18la), a modification linked to transcriptional activation of senescence‑associated genes.
3. Histone Lactylation Opens the p16 Promoter – Lactate accumulates when mitochondrial TCA cycle flux is impaired by mutant mtDNA. Elevated intracellular lactate fuels histone lactylation, which relaxes chromatin at the CDKN2A locus, increasing accessibility for transcription factors such as NF‑κB and C/EBPβ. This provides a mechanistic bridge between metabolic dysfunction and epigenetic remodeling that has not been tested in kidney cells.
4. Feedback Loop – Senescent podocytes secrete SASP factors (e.g., IL‑6, TGF‑β) that further suppress mitochondrial biogenesis via mTORC1 inhibition, exacerbating mtDNA damage and cementing the cycle.

Experimental Design

Model: Inducible podocyte‑specific expression of a pathogenic mtDNA mutator (PolG^D257A) in mice, combined with a fluorescent heteroplasmy reporter.

Interventions:

• Group A: mtDNA mutator only (control).
• Group B: mutator + mitochondrially targeted catalase (mCAT) to scavenge ROS.
• Group C: mutator + nucleoside supplementation to boost mtDNA copy number.
• Group D: mutator + STING inhibitor (C‑176).
• Group E: mutator + histone lactylation inhibitor (lactate dehydrogenase inhibitor, GSK‑2837808A).

Readouts (at 3, 6, 9 months):

• Heteroplasmy load by droplet digital PCR.
• Cytosolic mtDNA detection (qPCR of cytosolic fraction).
• cGAS‑STING activation (phospho‑TBK1, IFN‑β ELISA).
• Global histone lactylation (Western blot for H3K18la).
• p16INK4a and p21 mRNA/protein ( immunofluorescence, qPCR).
• Functional assays: albuminuria, glomerular filtration rate, podocyte foot‑process width (EM).

Expected Outcomes and Falsifiability

If our hypothesis is correct, groups C, D, and E will show:

• Significant reduction in cytosolic mtDNA and STING signaling versus Group A.
• Decreased H3K18la at the CDKN2A promoter (ChIP‑qPCR).
• Lower p16/p21 expression and attenuated SASP.
• Preserved glomerular function and reduced albuminuria.

Conversely, if mtDNA heteroplasmy does not drive senescence, manipulating mtDNA copy number, ROS, STING, or lactylation will not alter p16/p21 levels or renal phenotypes despite successful target engagement. This would falsify the claim that mtDNA dysfunction is the upstream initiator of the nuclear senescence program in podocytes, directing focus toward alternative nuclear‑centric mechanisms.